Evogene
Biotechnology company developing novel products for life science markets through the use of a unique CPB platform.
Launch date
Employees
Market cap
€14.1m
Enterprise valuation
€5m (Public information from Sep 2024)
Share price
$2.74 EVGN
Company register number 512838723
Rehovot Center District (HQ)
- hard tech
- biotechnology
- horizon europe
- sustainable development goals
- climate tech
- biotech and pharma
- core ai
- ai applications
- dietary supplements
- superfood
- predictive analytics
- genetics
- genome engineering
- drug development
- techbio
- ai drug discovery
- digital pharma
- organic
- techbio drug discovery
- biofuel
- crop protection
- crop
- gmo
- biopesticides
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.0m | <1m | 1.7m | 5.6m | 15.1m | 20.1m | 39.8m |
| % growth | 38 % | (11 %) | 80 % | 237 % | 168 % | 33 % | 98 % |
| EBITDA | (20.5m) | (26.8m) | (23.8m) | (22.8m) | (15.3m) | (16.5m) | (7.8m) |
| % EBITDA margin | (1971 %) | (2880 %) | (1424 %) | (404 %) | (101 %) | (82 %) | (20 %) |
| Profit | (23.4m) | (27.8m) | (26.6m) | (23.9m) | (19.0m) | (20.2m) | (12.5m) |
| % profit margin | (2248 %) | (2988 %) | (1590 %) | (423 %) | (126 %) | (100 %) | (31 %) |
| EV / revenue | 164.3x | 76.6x | 15.6x | 7.5x | 1.2x | 0.9x | 0.5x |
| EV / EBITDA | -8.3x | -2.7x | -1.1x | -1.9x | -1.2x | -1.1x | -2.4x |
| R&D budget | 20.0m | 23.9m | 20.8m | 20.8m | - | - | - |
| R&D % of revenue | 1919 % | 2566 % | 1241 % | 368 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
€903k | Grant | ||
$10.0m | Post IPO Equity | ||
* | N/A | $5.5m | Private Placement non VC |
| Total Funding | €903k | ||
